Sign in to continue:

Thursday, May 7th, 2026

Holley Inc. Reports Q1 2026 Results: Maintains Strong Margins, Updates Full-Year Guidance, and Advances Portfolio Optimization





Holley Inc. Q1 2026 Results: Detailed Investor Report

Holley Inc. Reports Strong Q1 2026 Results: Growth in Three Divisions, Margin Expansion, and Portfolio Optimization

Key Financial Highlights

  • Net Income: First quarter net income reached \$7.3 million, an increase of \$4.4 million year-over-year. This represents a significant improvement in profitability and is likely to be price sensitive for shareholders.
  • Adjusted EBITDA: Adjusted EBITDA was \$27.3 million, unchanged from the prior year, but the margin expanded to 18.5% from 17.8%, a 71 basis point increase. This margin expansion demonstrates improved efficiency and disciplined cost management.
  • Free Cash Flow: Free cash flow was \$(6.3) million, an improvement from \$(10.8) million the previous year, reflecting better cash management and operational improvements.
  • Cost Savings: The company delivered \$6.5 million in Q1 cost savings through purchasing, tariffs, and operational efficiencies.
  • Portfolio Optimization: Holley announced a portfolio optimization initiative expected to generate over \$15 million for reinvestment in growth. This includes exiting non-value-added businesses, consolidating sites, and reducing complexity. Management expects these actions to improve margins and support future growth.

Operational and Strategic Updates

  • Growth in Three of Four Divisions: Three out of four divisions reported growth, contributing to the company’s positive performance.
  • RX Acquisition: The acquisition of RX strengthens Holley’s Safety and Racing division and expands its European presence, a strategic move that could enhance long-term growth and market share.
  • Portfolio Rebalancing: The company expects portfolio rebalancing to generate over \$15 million to reinvest in growth areas, supporting future strategic initiatives.
  • Improved Free Cash Flow: Q1 2026 saw a \$4.5 million improvement in free cash flow compared to the same period last year, indicating better operational execution.

2026 Outlook & Guidance

  • Core Business Revenue Guidance: Remains unchanged, signaling confidence in ongoing operations despite portfolio adjustments.
  • Full-Year Guidance Updated: Holley updated its full-year guidance to reflect an anticipated \$15 million adjustment related to portfolio optimization. This change is likely to be closely watched by investors.
  • Adjusted EBITDA: Guidance for 2026 is set at \$127 – \$137 million, unchanged from previous estimates, indicating stability in earnings despite operational changes.
  • Capital Expenditures: Guidance for capital expenditures is \$24 – \$26 million for the year, also unchanged.
  • Interest Expense: Interest expense (excluding collar revaluation) is expected to be \$42 – \$47 million.
  • Core Business Growth Rate: Newly introduced this quarter, expected between ~2% to ~7%, excluding the impact from portfolio optimization adjustments.

Non-GAAP Measures and Reconciliations

Holley provides several non-GAAP financial measures (EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Bank-adjusted EBITDA Leverage Ratio, Adjusted Net Income, Adjusted Diluted EPS, and Free Cash Flow) to help investors evaluate performance and compare results between periods. These measures exclude impacts from items not indicative of ongoing operations, such as changes in fair value of warrant and earn-out liabilities, restructuring costs, and asset write-downs. Management uses these metrics to set forecasts and operational goals. Investors should note that these metrics are not prepared in accordance with GAAP and may differ from measures used by other companies.

Balance Sheet and Shareholder Equity

  • Total Liabilities and Stockholders’ Equity: \$1,178.8 million as of March 29, 2026.
  • Total Stockholders’ Equity: Increased to \$455.9 million, up from \$448.9 million last year, reflecting improved financial stability.
  • Bank-adjusted EBITDA Leverage Ratio: 3.84x, compared to 3.75x last year.

Shareholder Information and Price Sensitivity

  • Emerging Growth Company: Holley is identified as an emerging growth company, which may have implications for compliance and reporting standards.
  • Exhibit Press Release: The company furnished a press release as Exhibit 99.1 with detailed financials and operational highlights.
  • Conference Call: An investor conference call was announced, with a replay available, and financial information is regularly updated on the Holley investor relations website.

Risks and Forward-Looking Statements

Holley cautions that forward-looking statements are subject to risks and uncertainties. Actual results may differ due to factors currently unknown or deemed immaterial. Investors should not place undue reliance on these statements, and Holley undertakes no obligation to update them except as required by law.

Contacts

Conclusion

Holley Inc.’s Q1 2026 results reflect substantial improvement in profitability, margin expansion, disciplined cost control, and strategic portfolio optimization. The strong net income, expanded EBITDA margin, and improved free cash flow are likely to be positively received by investors and could impact share price. The RX acquisition and anticipated reinvestment from portfolio rebalancing further strengthen growth prospects.

Updated guidance and stable outlook reinforce confidence in the company’s trajectory. Investors should monitor developments related to portfolio optimization and capital allocation, as these may influence future performance and share value.


Disclaimer: This article is based on Holley Inc.’s public filings and press release for Q1 2026. It is intended for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to change and actual results may differ. Readers should conduct their own due diligence and consult with financial advisors before making any investment decisions.




View Holley Inc. Historical chart here



Lisata Therapeutics 2025 10-K/A – Executive Compensation, Board Governance, and Change in Control Benefits

LISATA THERAPEUTICS, INC. 10-K/A Filing: Key Highlights and ...

PURE Bioscience Reports Increased Q2 2026 Sales and USDA Certification for PURE Clean

PURE Bioscience Reports Fiscal Q2 2026 Results: Key Developm...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today